Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Nabriva Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sinovant’s multi-center, randomized, double-blind trial was designed to evaluate the safety and efficacy of intravenous (IV) to oral lefamulin compared to IV/oral moxifloxacin in 125 subjects with CABP.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Nabriva Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
